Manuscripts and Letters

2018 – Emily L. Heil, David P. Nicolau, Andras Farkas, Jason A. Roberts, Kerri A. Thom; Pharmacodynamic target attainment for cefepime, meropenem and piperacillin/tazobactam using a pharmacokinetic/pharmacodynamic-based dosing calculator in critically ill patients. Antimicrobial Agents and Chemotherapy, published online ahead of print on June 6, 2018

2016 – Andras Farkas, Gergely Daroczi, Philip Villasurda, Michael Dolton, Midori Nakagaki, Jason A Roberts; Comparative evaluation of the predictive performance of three different structural population pharmacokinetic models to predict future voriconazole concentrations. Antimicrobial Agents and Chemotherapy, published online ahead of print on September 6, 2016

2016 – Delgado-Valverde M, Torres E, Valiente-Mendez A, Almirante B, Gómez-Zorrilla S, Borrell N, Corzo JE, Gurgui M, Almela M, García-Álvarez L, Fontecoba-Sánchez MC, Martínez-Martínez L, Cantón R, Praena J, Causse M, Gutiérrez-Gutiérrez B, Roberts JA, Farkas A, Pascual Á, Rodríguez-Baño J; REIPI/GEIH-SEIMC BACTERAEMIA-MIC group; Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. 2016, Journal of Antimicrobial Chemotherapy, 71(2):521-30

2014 – Gloria Wong, Andras Farkas, Rachel Sussman, Gergely Daroczi, William W Hope, Jeffrey Lipman, Jason A Roberts; Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients. Antimicrobial Agents and Chemotherapy, published online ahead of print on 15 December 2014

2014 – Jason A Roberts, Mohd H Abdul-Aziz, Jeffrey Lipman, Johan W Mouton, Alexander A Vinks, Timothy W Felton,William W Hope,  Andras Farkas, Michael N Neely, Jerome J Schentag, George Drusano, Otto R Frey, Ursula Theuretzbacher,  Joseph L Kuti, on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases; Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. 2014,  The Lancet Infectious Diseases, 14 (6): 441 – 532

2012 – Farkas A, Successful target attainment of telavancin at elevated MICs: fact or fiction?  2012, Antimicrobial Agents and Chemotherapy, 56: 4560